Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial (Q33379689)

26 July 2017

Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial (English)

1 reference

26 July 2017

phase I clinical trial

0 references

1 reference

1 reference

Ta-Chiang Liu

3

0 references

John C Bell

18

object named as

John C Bell

1 reference

26 July 2017

Byeong-Ho Park

1

1 reference

26 July 2017

Taeho Hwang

2

1 reference

26 July 2017

Daniel Y Sze

4

1 reference

26 July 2017

Jae-Seok Kim

5

1 reference

26 July 2017

Hyuk-Chan Kwon

6

1 reference

26 July 2017

Sung Yong Oh

7

1 reference

26 July 2017

Sang-Young Han

8

1 reference

26 July 2017

Jin-Han Yoon

9

1 reference

26 July 2017

Sook-Hee Hong

10

1 reference

26 July 2017

Anne Moon

11

1 reference

26 July 2017

Kelly Speth

12

1 reference

26 July 2017

Chohee Park

13

1 reference

26 July 2017

Young-Joo Ahn

14

1 reference

26 July 2017

Manijeh Daneshmand

15

1 reference

26 July 2017

Byung Geon Rhee

16

1 reference

26 July 2017

Herbert M Pinedo

17

1 reference

26 July 2017

David H Kirn

19

1 reference

26 July 2017

19 May 2008

1 reference

Lancet Oncology Commission

26 July 2017

1 reference

26 July 2017

9

1 reference

26 July 2017

533-542

1 reference

26 July 2017

6

1 reference

Replication-selective virotherapy for cancer: Biological principles, risk management and future directions

26 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970107-4

7 January 2021

Recent progress in the battle between oncolytic viruses and tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970107-4

7 January 2021

Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970107-4

7 January 2021

Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970107-4

7 January 2021

Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970107-4

7 January 2021

Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970107-4

7 January 2021

Bioluminescence imaging of vaccinia virus: effects of interferon on viral replication and spread

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970107-4

7 January 2021

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970107-4

7 January 2021

Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970107-4

7 January 2021

Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970107-4

7 January 2021

Smallpox and pan-orthopox virus detection by real-time 3'-minor groove binder TaqMan assays on the roche LightCycler and the Cepheid smart Cycler platforms

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970107-4

7 January 2021

Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970107-4

7 January 2021

The dissociation of GM-CSF efficacy from toxicity according to route of administration: a pharmacodynamic study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970107-4

7 January 2021

Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970107-4

7 January 2021

Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970107-4

7 January 2021

Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970107-4

7 January 2021

Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970107-4

7 January 2021

Discovery of antivirals against smallpox

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970107-4

7 January 2021

A mechanism for the inhibition of fever by a virus

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970107-4

7 January 2021

Viruses with deletions in antiapoptotic genes as potential oncolytic agents.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970107-4

7 January 2021

Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970107-4

7 January 2021

Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970107-4

7 January 2021

Antibodies against vaccinia virus do not neutralize extracellular enveloped virus but prevent virus release from infected cells and comet formation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970107-4

7 January 2021

Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970107-4

7 January 2021

Immune response to poxvirus infections in various animals

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970107-4

7 January 2021

E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970107-4

7 January 2021

10.1016/S1470-2045(08)70107-4

Identifiers

DOI

1 reference

26 July 2017

1 reference